Case Result: Pharmacy’s Out-of-State Healthcare Fraud Allegations Contested as Improper, Case is Dismissed
Our Florida healthcare attorneys provided clearly showed that the healthcare fraud allegations were improper, and the case was dismissed.
Client pharmacy contacted the healthcare compliance attorneys at Chapman Law Group about being served with a DEA order to show cause. The pharmacist’s license was at severe risk of being taken away because of this order.
We negotiated with the DEA for over a year in order avoid its order to show cause. In doing so, we put the pharmacy in a position for compliance, which included drafting and executing a Corrective Action Plan; working on a memorandum of understanding with the DEA; recommending the pharmacy to use custom software for making and following biannual reports and keeping inventories; and understanding and following all requirements for documentation under DEA rules and regulations.
This information is a sample of our past results. Prospective clients may not obtain the same or similar results. Every case is different and each case must be evaluated and handled on its own merits. The circumstances of your case may differ from the results provided. The information provided has not been reviewed or approved by the State Bar.
Chapman Law Group contended that the government was unable to prove, “‘by a preponderance of the evidence,’” our client’s DEA registration should be denied solely because of his Medicare/Medicaid exclusion.
Our attorneys argued to the OIG that exclusion for the prescribed time period was unreasonable under OIG regulations, and that most factors that would lead to a greater exclusion period were inapplicable.
We successfully demonstrated to the DEA that the pharmacist had the financial capacity to operate a pharmacy and also fully understood his corresponding responsibilities in regarding to narcotic medication dispensing and record keeping.
Chapman Law Group’s Ronald W. Chapman Sr. and Juan Santos hosted a CLE session on DOH, DEA, Medicaid at the Florida Pharmacy Association Law & Regulatory Conference in Sarasota.
The CDC Guidelines for prescribing controlled substances like opioids, and the DEA/DOJ investigations that follow, are putting physicians and their pain patients in a regulatory crunch.
There’s a simple, short answer for whether pharmacies can, carte blanche, defer a patient’s co-pays and deductibles. That answer is NO. Why Can’t Co-Pays and